116313-94-1 Usage
Description
Nitecapone, also known as OR-462, is a pharmaceutical compound that functions as a selective inhibitor of the enzyme catechol O-methyl transferase (COMT). It is a yellow solid and was specifically patented for its use as an antiparkinson medication.
Uses
Used in Pharmaceutical Industry:
Nitecapone is used as an inhibitor for the treatment of Parkinson's disease. It helps manage the symptoms by inhibiting the enzyme COMT, which is responsible for the degradation of dopamine in the brain. By reducing the breakdown of dopamine, Nitecapone enhances the effectiveness of levodopa, a primary medication used in the treatment of Parkinson's disease, and improves the overall motor function and quality of life for patients.
In vitro
Nitecapone (1-100 μM) reducesd GSH (reduced glutathione) depletion induced by ROO-by 11-38% and oxidation to oxidized glutathione (GSSG) by 32-45%.MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Biological activity
Nitecapone (OR-462) is a short-acting, orally active, catechol-O-methyltransferase (COMT) inhibitor with gastrointestinal protective and antioxidant activity. Nitecapone (OR-462) scavenges reactive oxygen species and nitric oxide and prevents lipid peroxidation.
Check Digit Verification of cas no
The CAS Registry Mumber 116313-94-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,6,3,1 and 3 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 116313-94:
(8*1)+(7*1)+(6*6)+(5*3)+(4*1)+(3*3)+(2*9)+(1*4)=101
101 % 10 = 1
So 116313-94-1 is a valid CAS Registry Number.
InChI:InChI=1/C12H11NO6/c1-6(14)9(7(2)15)3-8-4-10(13(18)19)12(17)11(16)5-8/h3-5,16-17H,1-2H3
116313-94-1Relevant articles and documents
Pharmaceutical compounds for treating copd
-
, (2008/06/13)
Use of an MPO inhibitor for the treatment of COPD.
Synthesis of Some Novel Potent and Selective Catechol O-Methyltransferase Inhibitors
Baeckstroem, Reijo,Honkanen, Erkki,Pippuri, Aino,Kairisalo, Pekka,Pystynen, Jarmo,et al.
, p. 841 - 846 (2007/10/02)
A series of disubstituted catechol derivatives was synthesized and tested as potential COMT inhibitors.The most active compounds were more than 1000 times more potent (IC 50 = 3-6 nM) in vitro than the known COMT inhibitor, 3',4'-dihydroxy-2-methylpropiop